Why the study?
Does avosentan reduce urinary albumin excretion rate in patients with diabetic nephropathy and macroalbuminuria?
Does avosentan reduce urinary albumin excretion rate in patients with diabetic nephropathy and macroalbuminuria?
Avosentan added to standard ACEI/ARB therapy significantly reduces urinary albumin excretion in patients with diabetic nephropathy and macroalbuminuria, though higher doses are associated with peripheral edema.
Answers are grounded in this paper and cite their sources.
Avosentan added to ACEI/ARB reduces UAER in macroalbuminuric diabetic nephropathy; extends endothelin antagonism evidence with edema caution at higher doses.
Despite the first-line use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), there is still a large need to improve the prevention and progression of diabetic nephropathy and its associated cardiovascular events. Endothelin antagonists have shown anti-inflammatory, antifibrotic, and antiproteinuric effects in experimental studies. This study was a randomized, placebo-controlled, double-blind, parallel-design, dosage-range study of the effect of the endothelin-A antagonist avosentan (SPP301) on urinary albumin excretion rate (UAER) in patients with diabetic nephropathy. We randomly assigned 286 patients with diabetic nephropathy, macroalbuminuria (UAER 0.2 to 5.6 mg/min), and BP <180/110 mmHg to 12 wk of avosentan (5, 10, 25, and 50 mg) or placebo, in addition to standard ACEI/ARB therapy. Relative to baseline, all avosentan dosages decreased mean relative UAER (-16.3 to -29.9%) compared with placebo (35.5%). Median relative UAER decreased with all avosentan dosages (-28.7 to -44.8%) compared with placebo (12.1%). Creatinine clearance and BP were unchanged at 12 wk. The main adverse events were peripheral edema (12%), mainly with high (>/=25 mg) dosages of avosentan; significant increases in liver enzymes did not occur. Twenty-one (7.3%) patients experienced adverse events that led to withdrawal from study medication. In summary, the endothelin-A antagonist avosentan given in addition to standard ACEI/ARB treatment decreases UAER in patients with diabetic nephropathy and macroalbuminuria.
No takes yet. Share an insight, caveat, or question.
WENZEL et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: